Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses the burden of high-cost biologics.
Transcript:What’s the burden of out-of-pocket costs for patients who rely on biologic drugs?
I think from the patient perspective…there’s a big surprise for patients. I think we’ve seen a significant rise of high-deductible health plans, and a lot of people with chronic diseases purchasing those high-deductible health plans, in part, because the premiums associated with those high-deductible health plans are significantly lower. Patients have begun to rely on needing that high deductible with their copay assistance programs.
So, I think what we’re most afraid of, most recently with out-of-pocket costs regarding these specialty drugs, is that patients have come to rely on a way of getting by the high-deductible health plan that may be going away, and they may not be aware of that.
In our advocacy efforts, one of the things we’re working on is to educate patients that they really have to look into their health plan, especially their high-deductible health plans, and understand if copay accumulators are being applied to that policy.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.